A systematic approach to tuberculosis vaccine development.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41308617.
- Also identified by DOI 10.1016/j.cell.2025.10.024.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
M. tuberculosis is once again the leading infectious cause of death worldwide despite the existence of a licensed vaccine (BCG). In this issue of Cell, Vidal et al. systematically evaluate 42 candidate antigens and develop a trivalent mRNA vaccine that demonstrates effective and durable protection from tuberculosis in several mouse models. This vaccine also enhances protection conferred by BCG.
Medical subject headings
- Tuberculosis Vaccines
- Mycobacterium tuberculosis
- Vaccine Development
- Tuberculosis